ReviewJournal of atrial fibrillation
New Technologies In Atrial Fibrillation Ablation.
Review in Journal of atrial fibrillation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is a major public health issue worldwide, the incidence of which is likely to continue to rise. With the birth of pulmonary vein isolation(PVI), cardiac ablation has emerged as key strategy for the treatment of AF. PVI using traditional point by point radiofrequency ablation is time consuming and technically challenging. Refining patient selection for PVI also remains an important goal. New ablative strategies using catheter-based balloon technologies, such as cryothermy and laser-based systems, may simplify PVI. In addition, new MRI-based techniques offer the hope of refining patient selection prior to ablation. Lastly, FIRM mapping represents an entirely new approach to AF ablation via the targeting of mechanisms that perpetuate AF rather than simply targeting triggers alone.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.